Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human albumin–G-CSF fusion protein
- Development stage
- Unknown
- Lead developer
- CanSino Biologics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Recombinant human albumin–G-CSF fusion protein (also known as FY01 or M-GCSF) is a long-acting granulocyte colony-stimulating factor (G-CSF) analogue developed by Sino-Fugen Biotechnology and its partners. The molecule is a recombinant fusion protein consisting of human G-CSF covalently linked to recombinant human serum albumin (HSA). This design leverages the long circulatory half-life of albumin to extend the duration of action of G-CSF, thereby reducing the frequency of administration required to manage neutropenia compared to short-acting filgrastim. FY01 acts as an agonist at the G-CSF receptor (G-CSFR), stimulating the survival, proliferation, and differentiation of neutrophil lineage cells in the bone marrow. It is currently being evaluated in clinical trials for the prevention of chemotherapy-induced neutropenia (CIN) in patients with solid tumors, including breast cancer.
- Other names
- recombinant human serum albumin-granulocyte colony-stimulating factor fusion proteinAlbu-G-CSF重组人血清白蛋白-粒细胞刺激因子融合蛋白
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on recombinant human albumin–G-CSF fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human albumin–G-CSF fusion protein.